We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Expedeon AG Adds ELISA-ONE™ Next Generation Cell Signalling Assay Technology to Product Offering

Expedeon AG Adds ELISA-ONE™ Next Generation Cell Signalling Assay Technology to Product Offering content piece image
Image credit: Expedeon
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute
Expedeon AG announced it has added ELISA-ONE™ to its product offering. The technology was developed by TGR BioSciences, which was acquired by Expedeon in May 2018.

This product enables Expedeon to address new markets, such as the cell signalling market, at a critical time in the company’s growth and development. The cell signalling market was reported to be USD 2.53 billion in 2017 and is forecast to reach USD 3.51 billion by 2022 at a CAGR of 6.8%.[1] The immunoassay market was estimated to be USD $1.6 to $1.7 billion in 2017 according to multiple reports. Amongst the market segments analysed, ELISA was found to be the most widely conducted immunoassay procedure according to one survey with the majority of users focusing on immunology, molecular biology, cell biology, biochemistry and cell signalling.2 From this we could estimate that the addressable market for the ELISA-ONE is in the range of $300 million USD.

ELISA-ONE™ next generation ready-to-use ELISA kits have been developed for fast detection of key intracellular proteins in major signalling pathways. Monitoring cell signalling pathways is essential for understanding many cellular processes and disease states and is therefore vital to help further basic research and drug discovery.

Immunoassays are a gold-standard method for the detection of proteins and biomarkers in discovery processes. However, onerous multi-step and error-prone traditional ELISA protocols limit throughput and data consistency, creating a critical bottleneck and significantly impeding the transfer of assays from development into high-throughput screens.

Additionally, researchers investigating intracellular proteins in signalling pathways often face further challenges with limited availability of, and unoptimized or unvalidated, antibody pairs. Powered by Expedeon’s CaptSure™ technology, ELISA-ONE™ kits provide all reagents and optimized antibody pairs in one ready-to-use kit. This will save researchers valuable time, eliminating the need to evaluate different antibodies and offering a simplified solution for performing ELISA assays. The whole protocol takes less than 90 minutes, with far fewer handling steps than traditional ELISA methods.

Dr Heikki Lanckriet, CEO of Expedeon, said: “The addition of the ELISA-ONE™ technology to the Expedeon offering further integrates the Expedeon product portfolio, enriching the value for our customers’ daily research work. This technology provides a solution to the most common issues that many researchers face, whilst maintaining the sensitivity they need in order to produce data they can trust. The addition of this kit to our portfolio supports our contribution to expediting cancer biomarker research, which is vital to the global effort to identify successful treatments and cures.”

[1] Cell Signalling Market, Markets and Markets, global forecast to 2022
[2] 2018 Immunoassay market overview, Biocompare, https://www.biocompare.com/Editorial-Articles/348411-Survey-Sizes-Up-Immunoassay-Market/